An AI-driven tool that tailors antidepressant treatment to individual patients was shown to improve outcomes for people with depression, compared to standard treatment, in a major international trial.

A clinical trial is underway to test a drug-free stimulation therapy to see if it can relieve symptoms of postpartum depression.

A web-based tool that incorporates patient preference in antidepressant selection was associated with a significant decrease ...

Data are limited, however. In mice, ingesting exercise mimetics appeared to improve depressive-like behaviors, and the ...

Agreement further extends NetraMark’s portfolio of AI-driven projects in depression and central nervous system (CNS) disorders TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the ...

Live Science spoke with the scientists behind an upcoming clinical trial testing an immune therapy for depression.

Prof. Dr. Guido van Wingen discusses the potential of, and barriers to, the use of AI in transforming the treatment of depression ...

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its ...

A new mom shares how the recently approved two-week postpartum depression drug was a game-changer to combat a notably common condition during a tender phase of life.

In recent years, a drug called ketamine has attracted attention because it can reduce depressive symptoms very quickly. Unlike traditional antidepressants, which may take weeks to work, ketamine can ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

Agreement further extends NetraMark's portfolio of AI-driven projects in depression and central nervous system (CNS) disorders TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the ...